---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-065186"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:45:28.501613+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics receives FDA Breakthrough Therapy Designation for nomlabofusp in Friedreich's ataxia

## Summary
- FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich's ataxia.
- FDA aligned on using skin FXN as a surrogate endpoint to support BLA seeking accelerated approval.
- Planned BLA submission remains on track for June 2026; topline open-label data expected Q2 2026.
- Global confirmatory Phase 3 study to initiate Q2 2026; first patient dosing targeted mid-2026.
- U.S. launch targeted for first-half 2027, if approved; estimated 5,000 U.S. patients with FA.

## SEC filing metadata
- accession: 0001193125-26-065186
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/0001193125-26-065186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/lrmr-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-065186
- JSON: https://secwatch.observer/filing/0001193125-26-065186.json
- Plain text: https://secwatch.observer/filing/0001193125-26-065186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.